Design Therapeutics (DSGN)
(Delayed Data from NSDQ)
$5.79 USD
-0.15 (-2.53%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $5.78 -0.01 (-0.17%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
DSGN 5.79 -0.15(-2.53%)
Will DSGN be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for DSGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DSGN
Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a Bet
Design Therapeutics, Inc. (DSGN) Upgraded to Buy: Here's What You Should Know
DSGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for DSGN
Design Therapeutics Reports Strong Q3 and Pipeline Progress
Design Therapeutics reports Q3 EPS (23c), consensus (24c)
Design Therapeutics reports Q3 EPS (23c), consensus (24c)
Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
Noteworthy Tuesday Option Activity: DSGN, SPHR, LAD